Could a shock drug help ARDS patients breathe easier?

NCT ID NCT05241067

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called centhaquine in 80 adults with moderate to severe ARDS, a life-threatening lung condition. The drug is added to standard care to see if it improves oxygen levels and reduces deaths. Participants must be in the ICU and start treatment within 48 hours of diagnosis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••